<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050501</url>
  </required_header>
  <id_info>
    <org_study_id>NL64702.058.18</org_study_id>
    <nct_id>NCT04050501</nct_id>
  </id_info>
  <brief_title>Non-invasive Vagus Nerve Stimulation in Acute Ischemic Stroke</brief_title>
  <acronym>NOVIS</acronym>
  <official_title>Non-invasive Vagus Nerve Stimulation in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands Organisation for Scientific Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ElectroCore INC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study will be to investigate whether treatment with non-invasive&#xD;
      vagus nerve stimulation (nVNS) on top of best medical practice in acute ischemic stroke&#xD;
      patients results in less infarct growth in the penumbra and smaller infarct volumes compared&#xD;
      with those of patients not treated with nVNS. The study will be a prospective randomized&#xD;
      clinical trial with blinded outcome assessment (PROBE design). 150 patients will be&#xD;
      randomized to nVNS with the gammaCore Sapphire™ device on top of best medical practice versus&#xD;
      best medical practice alone (including intravenous thrombolysis and/or thrombectomy if&#xD;
      indicated). If patients are randomized to nVNS, two stimulations of two minutes each will be&#xD;
      applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will&#xD;
      be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The&#xD;
      stimulation side in the neck will be the radiological side of the stroke. The primary&#xD;
      endpoint will be the final infarct volume on MRI scan on day 5 of patients treated with nVNS&#xD;
      compared with those of patients not treated with VNS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>PROBE design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct volume</measure>
    <time_frame>On day 5</time_frame>
    <description>Final infarct volume on MRI scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of nVNS</measure>
    <time_frame>On day 5</time_frame>
    <description>Reached if more than 75% of the nVNS treated patients complete treatment for five days or until discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of nVNS</measure>
    <time_frame>On day 5</time_frame>
    <description>Reached if less than 10% of the patients treated with nVNS has to abort treatment due to side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS (National Institutes of Health Stroke Scale) on day 5</measure>
    <time_frame>On day 5</time_frame>
    <description>The scale runs from 0-42 and quantifies stroke severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome (modified Rankin Scale, mRS) on day 90</measure>
    <time_frame>On day 90</time_frame>
    <description>The scale runs from 0-6 and quantifies disabilities:&#xD;
0 - No symptoms&#xD;
- No significant disability. Able to carry out all usual activities, despite some symptoms&#xD;
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities&#xD;
- Moderate disability. Requires some help, but able to walk unassisted&#xD;
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted&#xD;
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent&#xD;
- Dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of seizures in the first 90 days</measure>
    <time_frame>On day of admission, day 5 and day 90</time_frame>
    <description>This will be asked to patients and their physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of headache in the first 90 days</measure>
    <time_frame>On day of admission, day 5 and day 90</time_frame>
    <description>A questionnaire will be taken adjusted from van Os et al., neurology 2016</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of depression in the first 90 days</measure>
    <time_frame>On day 90</time_frame>
    <description>HADS (Hospital Anxiety and Depression Scale) questionnaire will be taken. The scale runs from 0-21 and defines the risk of having a depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after 90 days</measure>
    <time_frame>On day 90</time_frame>
    <description>EQ5D-5L questionnaire will be taken. This questionnaire defines a health index based on different questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive status on day 90</measure>
    <time_frame>On day 90</time_frame>
    <description>TICS questionnaire will be taken. This questionnaire can assess cognitive status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penumbra recovery</measure>
    <time_frame>On day 3</time_frame>
    <description>Proportion of patients in whom &lt;50% of the penumbra turned into ischemic core on non-contrast CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood-brain barrier measurement</measure>
    <time_frame>On day 3</time_frame>
    <description>Degree of blood-brain barrier leakage on day three measured with CTP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>non-invasive Vagus Nerve Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-invasive Vagus Nerve Stimulation on top of best medical practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best medical practice alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>non-invasive Vagus Nerve Stimulator</intervention_name>
    <description>Two stimulations of two minutes each will be applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The stimulation side in the neck will be the radiological side of the stroke.</description>
    <arm_group_label>non-invasive Vagus Nerve Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ischemic stroke&#xD;
&#xD;
          -  NIHSS ≥1&#xD;
&#xD;
          -  Perfusion deficit on the admission CTP scan; the penumbra must comprise at least 1/3&#xD;
             of the total ischemic area (ischemic core and penumbra)&#xD;
&#xD;
          -  The infarct has to comprise the anterior circulation&#xD;
&#xD;
          -  Treatment has to start &lt;12 hours after stroke onset&#xD;
&#xD;
          -  Patients or their representatives need to give their informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A life expectancy of less than three months&#xD;
&#xD;
          -  mRS &gt;2 prior to admission&#xD;
&#xD;
          -  Contra-indication for contrast CT&#xD;
&#xD;
          -  Contra-indications for VNS:&#xD;
&#xD;
               -  An active implantable medical device such as a pacemaker, deep brain stimulator,&#xD;
                  or any implanted electronic device&#xD;
&#xD;
               -  Symptomatic stenosis or dissection of the carotid artery (in these patients the&#xD;
                  other side will be stimulated unless a significant stenosis on the other side is&#xD;
                  present as well)&#xD;
&#xD;
               -  Structural abnormality e.g. lymphadenopathy, previous surgery or abnormal anatomy&#xD;
                  (in these patients the other side will be stimulated)&#xD;
&#xD;
               -  Metal cervical spine hardware or metallic implant near the stimulation site&#xD;
&#xD;
               -  Cervical vagotomy (in these patients the other side will be stimulated)&#xD;
&#xD;
               -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marieke JH Wermer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne van der Meij, PhD</last_name>
    <phone>0031715261899</phone>
    <email>novis@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marieke JH Wermer, MD PhD</last_name>
    <phone>0031715262197</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marieke JH Wermer, MD PhD</last_name>
      <phone>0031715262197</phone>
      <email>m.j.h.wermer@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Anne van der Meij, MD</last_name>
      <phone>0031715262197</phone>
      <email>a.van_der_meij@lumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Marieke JH Wermer, MD</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>Brain infarction</keyword>
  <keyword>Brain ischemia</keyword>
  <keyword>Vagus nerve stimulation</keyword>
  <keyword>Penumbra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

